Patent ID: 6503882
Filing Date: 2003-01-07
Classification: A61K,A61P

Abstract:
A method for treating the T-cells of a human subject infected with Human Immunodeficiency Virus, comprisingcontacting said T-cells with a molecule in an amount effective to stimulate immune function of the T-cells, said amount being below a concentration which causes detectable cytotoxicity of said T-cells, said molecule having the formula: wherein Y is a group of the formula: and each R1, R2, R3, R4, R5, R6, R7, and R8 is, independently, a group which does not significantly interfere with site specific recognition by DP-IV; wherein X comprises an amino acid or a peptide that mimics the site of a substrate recognized and cleaved by CD26; and wherein T is a group of the formula: wherein B is boron, and each D1 and D2 is, independently, a hydroxyl group or a group capable of being hydrolyzed to a hydroxyl group at physiological pH; a group of the formula: wherein G is either H, fluorine (F), or an alkyl group containing 1 to 20 carbon atoms and optional heteroatoms which can be N, S, or O; a group of the formula: a group of the formula: wherein R is a substituted or unsubstituted alkyl or aryl group; or a group of the formula: